GlassScriptPhysician profile
Vijaya L Murthy
NPI 1699966887
$9,409.67
in general payments reported to CMS, 2019-2025
20 companies · $2,221 in 2025
The $2,221 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $305 · 2021: $810 · 2022: $1,203 · 2023: $2,363 · 2024: $2,112 · 2025: $2,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,695.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,983.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,414.71 | 2021-2025 | Saphnelo, Flumist Quadrivalent |
| Amgen INC. | $1,259.78 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Aurinia Pharma U.S., INC. | $1,106.64 | 2021-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $668.80 | 2019-2025 | Benlysta, Nucala |
| Janssen Biotech, INC. | $392.26 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Horizon Therapeutics Plc | $321.66 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $307.00 | 2021-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $226.74 | 2024 | Purified Cortrophin Gel |
| Genentech, INC. | $137.40 | 2025 | Gazyva |
| Janssen Scientific Affairs, LLC | $130.68 | 2025 | Tremfya |
| Lilly USA, LLC | $128.57 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $96.39 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $95.43 | 2023-2025 | Strensiq |
| Octapharma USA, INC. | $39.58 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.76 | 2019 | |
| Travere Therapeutics, INC. | $24.93 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $21.57 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijaya Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.